Wanbury

Why is Wanbury Ltd falling/rising?

As of 24-Aug, Wanbury Ltd's stock price has risen by 1.49% today, despite a negative trend over the past month with a 19.08% decline. The stock shows mixed signals, being above some moving averages but below others, indicating declining investor participation.

As of 24-Aug, Wanbury Ltd's stock price is currently rising, with a change of 3.95, representing a 1.49% increase. This rise comes despite the stock having underperformed its sector by 0.32% today and experiencing a consecutive fall over the last three days, during which it has lost 2.04%. <BR><BR>The stock touched an intraday high of Rs 270.7, indicating some upward movement within the trading day. However, it is important to note that the stock's performance over the past month has been negative, with a decline of 19.08%, contrasting with a positive return of 1.72% for the Sensex during the same period. <BR><BR>Additionally, the stock's delivery volume has significantly decreased, falling by 61.34% against the 5-day average, which suggests a decline in investor participation. While the stock is currently above its 5-day and 200-day moving averages, it remains below its 20-day, 50-day, and 100-day moving averages, indicating mixed signals regarding its short-term performance. <BR><BR>Overall, while there is a slight rise in the stock price today, the broader context shows a concerning trend of declining performance and investor participation.

Which are the latest news on Wanbury?

Should I buy, sell or hold Wanbury Ltd?

Who are in the management team of Wanbury?

The management team of Wanbury includes N K Puri (Independent Director), K Chandran (Vice Chairman & Whole Time Director), Jitendra J Gandhi (Company Secretary & Compliance Officer), and several other Independent Directors: Pallavi Shedge, Binod Chandra Maharana, Manisha Juvekar, Anupam Vaidya, and Pravin Dilip Pawar. This diverse team brings a wide range of expertise to the company.

The management team of Wanbury includes the following members:<BR><BR>1. **N K Puri** - Independent Director<BR>2. **K Chandran** - Vice Chairman & Whole Time Director<BR>3. **Jitendra J Gandhi** - Company Secretary & Compliance Officer<BR>4. **Pallavi Shedge** - Independent Director<BR>5. **Binod Chandra Maharana** - Independent Director<BR>6. **Manisha Juvekar** - Independent Director<BR>7. **Anupam Vaidya** - Independent Director<BR>8. **Pravin Dilip Pawar** - Independent Director<BR><BR>This team brings a diverse range of expertise to the company. If you need more specific information about any of the members or their roles, feel free to ask!

What does Wanbury do?

Wanbury Ltd is a Micro Cap pharmaceutical company, incorporated in 1988, specializing in pharmaceuticals and biotechnology. As of June 2026, it reported net sales of 166 Cr and a net profit of 3 Cr, with a market cap of INR 923 Cr.

Overview:<BR>Wanbury Ltd is engaged in pharmaceutical and related activities, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>Wanbury Ltd was incorporated in August 1988 and was formerly known as Pearl Organics Limited, adopting its current name in September 2004. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 166 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 3 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 923 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 20.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 2.77<BR>- Return on Equity: 72.53%<BR>- Price to Book: 15.40<BR><BR>Contact Details:<BR>Address: BSEL Tech Park B-Wing 10th Flr, Sector 30 A Opp Vashi Rly Stat Navi Mumbai Maharashtra : 400703<BR>Tel: 91-22-67942222<BR>Email: shares@wanbury.com<BR>Website: http://www.wanbury.com

Who are the peers of the Wanbury?

Wanbury's peers include Bajaj Healthcare, Sigachi Industries, Themis Medicare, Bharat Parenter, Kopran, Anuh Pharma, Anlon Healthcare, Shree Ganesh Remedies, Remus Pharma, and Influx Health. In terms of management risk, growth, and capital structure, Wanbury shows average performance compared to its peers, with a 1-year return of 0.54%.

Peers: The peers of Wanbury are Bajaj Healthcare, Sigachi Indust., Themis Medicare, Bharat Parenter., Kopran, Anuh Pharma, Anlon Healthcare, Shree Ganesh Rem, Remus Pharma, and Influx Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Anuh Pharma and Shree Ganesh Rem, while Average management risk is found at Bajaj Healthcare, Sigachi Indust., Themis Medicare, Wanbury, Kopran, Anlon Healthcare, Remus Pharma, and the rest. Below Average management risk is noted for Bharat Parenter. In terms of growth, Excellent growth is seen at Anlon Healthcare, while Average growth is found at Wanbury and the rest, and Below Average growth is observed at Bajaj Healthcare, Sigachi Indust., Themis Medicare, Bharat Parenter., Kopran, Anuh Pharma, Shree Ganesh Rem, Remus Pharma, and the rest. For capital structure, Excellent capital structure is noted at Sigachi Indust., Anuh Pharma, Shree Ganesh Rem, and the rest, while Good capital structure is found at Kopran and Anlon Healthcare, and Below Average capital structure is observed at Wanbury, Bajaj Healthcare, Themis Medicare, Bharat Parenter., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Kopran at 14.73%, while the peer with the lowest is Bajaj Healthcare at -27.95%. Wanbury's own 1-year return is 0.54%, which is higher than Bajaj Healthcare but lower than Kopran. Additionally, peers with negative six-month returns include Wanbury, Anuh Pharma, and Shree Ganesh Rem.

How big is Wanbury?

As of 14th August, Wanbury Ltd has a market capitalization of 916.48 Cr, with net sales of 629.82 Cr and a net profit of 42.99 Cr reported in the latest four quarters. Shareholder's funds are 59.27 Cr, and total assets amount to 406.88 Cr for the annual period ending March 2025.

As of 14th August, Wanbury Ltd has a market capitalization of 916.48 Cr and is classified as a Micro Cap company.<BR><BR>In the latest four quarters, Wanbury reported net sales of 629.82 Cr and a net profit of 42.99 Cr.<BR><BR>For the latest annual period ending March 2025, Wanbury's shareholder's funds amounted to 59.27 Cr, while total assets were reported at 406.88 Cr.

When is the next results date for Wanbury Ltd?

The next results date for Wanbury Ltd is 11 August 2026.

The next results date for Wanbury Ltd is scheduled for 11 August 2026.

Is Wanbury technically bullish or bearish?

As of December 4, 2025, Wanbury's technical trend is mildly bearish, indicated by bearish momentum from the weekly MACD and KST, while daily moving averages and monthly indicators also reflect a cautious outlook.

As of 4 December 2025, the technical trend for Wanbury has changed from bearish to mildly bearish. The current technical stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish momentum, while the monthly MACD and Bollinger Bands suggest a mildly bearish outlook. The daily moving averages also reflect a mildly bearish sentiment. The lack of clear signals from the RSI and no trends in Dow Theory and OBV further support the neutral stance in the short term. Overall, the indicators suggest a cautious approach as the stock remains below its previous highs.

How has been the historical performance of Wanbury?

Wanbury's historical performance shows growth in net sales and operating income, increasing from 499.65 Cr in Mar'23 to 599.51 Cr in Mar'25. However, profitability declined, with profit before tax dropping to 29.55 Cr in Mar'25, and total liabilities rose to 406.88 Cr, indicating mixed financial health.

Answer:<BR>The historical performance of Wanbury shows a fluctuating trend in key financial metrics over the years, with notable changes in net sales, profits, and overall financial health.<BR><BR>Breakdown:<BR>Wanbury's net sales increased from 499.65 Cr in Mar'23 to 599.51 Cr in Mar'25, reflecting a positive growth trajectory. Total operating income followed a similar pattern, rising to 599.51 Cr in Mar'25 from 499.65 Cr in Mar'23. However, the company faced challenges with profitability, as operating profit (PBDIT) rose to 79.80 Cr in Mar'25 from 24.08 Cr in Mar'23, but profit before tax dropped to 29.55 Cr in Mar'25 from 56.34 Cr in Mar'24. Profit after tax also decreased to 30.53 Cr in Mar'25 from 55.96 Cr in Mar'24. The company's total liabilities increased to 406.88 Cr in Mar'25 from 337.62 Cr in Mar'24, while total assets also rose to 406.88 Cr in Mar'25 from 337.62 Cr in Mar'24, indicating a growing balance sheet. Cash flow from operating activities improved to 26.00 Cr in Mar'25 from 4.00 Cr in Mar'24, although cash flow from investing activities showed a significant outflow of -51.00 Cr in Mar'25. Overall, Wanbury's financial performance reflects a mix of growth in sales and operating income, alongside challenges in profitability and increasing liabilities.

Is Wanbury overvalued or undervalued?

As of November 6, 2025, Wanbury is considered undervalued with an attractive valuation grade, supported by a PE ratio of 20.53, strong growth potential indicated by a PEG ratio of 0.41, and impressive operational efficiency metrics like a 27.43% ROCE and 51.53% ROE, especially when compared to its more expensive peers like Sun Pharma and Divi's Laboratories.

As of 6 November 2025, the valuation grade for Wanbury has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued. Key ratios supporting this assessment include a PE ratio of 20.53, an EV to EBITDA of 11.90, and a PEG ratio of 0.41, which suggests strong growth potential relative to its price.<BR><BR>In comparison to its peers, Wanbury's valuation stands out favorably against Sun Pharma Industries, which is considered expensive with a PE ratio of 35.02, and Divi's Laboratories, which is categorized as very expensive with a PE ratio of 79.09. Additionally, while Wanbury's ROCE is an impressive 27.43% and ROE is a remarkable 51.53%, these figures further highlight its operational efficiency and profitability relative to its peers. Despite recent underperformance against the Sensex in the year-to-date period, Wanbury's long-term returns over three and five years significantly outperform the index, reinforcing its attractive valuation.

Are Wanbury latest results good or bad?

Wanbury's latest results show strong annual growth, with a 118.3% increase in Profit Before Tax and a 23.90% rise in net sales. However, recent quarter-on-quarter declines in net sales and profit raise concerns, leading to a cautious outlook.

Wanbury's latest results present a mixed picture. On one hand, the company has shown significant growth in key financial metrics compared to previous quarters. For the quarter ending June 2025, Wanbury reported a Profit Before Tax (PBT) of Rs 13.26 crore, which is an impressive increase of 118.3% compared to the average PBT from the prior four quarters. Similarly, the Profit After Tax (PAT) rose by 76.7% to Rs 13.49 crore.<BR><BR>Additionally, Wanbury's net sales for the latest six months reached Rs 335.18 crore, reflecting a year-on-year growth of 23.90%. The cash and cash equivalents also improved, reaching Rs 12.83 crore, indicating better short-term liquidity.<BR><BR>However, there are concerns regarding the quarter-on-quarter performance. Wanbury experienced a decline in net sales by 5.13% and a significant drop in consolidated net profit by 33.42% compared to the previous quarter. These downward trends in key metrics suggest challenges in maintaining momentum.<BR><BR>Despite the overall positive annual growth, the recent quarter's performance and the 'Sell' call issued by MarketsMOJO indicate that there may be caution warranted regarding the stock. Therefore, while there are strong annual results, the recent quarterly performance raises some red flags.

Who are the top shareholders of the Wanbury?

The top shareholders of Wanbury include Expert Chemicals (India) Pvt Ltd with 30.53%, individual investors with 41.78%, and public shareholder Suresh Bhatia at 3.58%. Additionally, 7 Foreign Institutional Investors hold 1.55%, while pledged promoter holdings are at 76.74%.

The top shareholders of Wanbury include a mix of promoters and individual investors. The largest promoter is Expert Chemicals (India) Pvt Ltd, holding 30.53% of the shares. Additionally, individual investors collectively hold 41.78% of the company. The highest public shareholder is Suresh Bhatia, who owns 3.58%. There are also 7 Foreign Institutional Investors (FIIs) with a combined holding of 1.55%, while mutual funds currently do not hold any shares in the company. The pledged promoter holdings stand at 76.7355%.

Has Wanbury declared dividend?

Yes, Wanbury Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of July 29, 2010. However, the dividend yield is 0%, indicating that returns have primarily come from price appreciation rather than dividend income.

Wanbury Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: Jul-29-2010<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 5.38%, the dividend return was 0%, resulting in a total return of 5.38%.<BR><BR>In the 1-year period, the price return was 103.38%, the dividend return was 0%, resulting in a total return of 103.38%.<BR><BR>In the 2-year period, the price return was 420.47%, the dividend return was 0%, resulting in a total return of 420.47%.<BR><BR>In the 3-year period, the price return was 337.36%, the dividend return was 0%, resulting in a total return of 337.36%.<BR><BR>In the 4-year period, the price return was 179.36%, the dividend return was 0%, resulting in a total return of 179.36%.<BR><BR>In the 5-year period, the price return was 1328.57%, the dividend return was 0%, resulting in a total return of 1328.57%.<BR><BR>Overall, while Wanbury Ltd has declared a dividend, the dividend yield remains at 0%, indicating that the returns have primarily come from price appreciation rather than dividend income. The total returns over various periods show significant growth, particularly over the longer term.